Press Releases
CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies
CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and ProBioGen. A premier German service and technology provider, announced a multi-year research collaboration focused on the development of novel in...
Press Releases
Samsung Bioepis secures FDA approval for cancer drug Ontruzant
The US FDA has granted approval for Samsung Bioepis to use Ontruzant (trastuzumab-dttb) to treat a range of cancers. Ontruzant, which will be marketed in the US by Merck, is a biosimilar to Roche’s Herceptin. It...
Press Releases
Sartorius Stedim Biotech Introduces BIOSTAT® RM TX with Flexsafe® RM TX for Producing Consistent Quality Cellular Products
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry announced the launch of the BIOSTAT® RM TX single-use bioreactor, a new wave mixed system developed specifically for closed, automated expansion of consistent quality cell products such...
Press Releases
Niche Biometric CRO launches dedicated pharmacovigilance business
Quanticate, a leading global data-focused clinical research organisation (CRO) has launched QVigilance to provide dedicated pharmacovigilance (PV) and risk management services. QVigilance will be focused on supporting small and mid-size companies transitioning from clinical trials to...
Press Releases
Eisai’s New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
Eisai Co., Ltd. and Purdue Pharma L.P. announced that a new drug application has been submitted to the U.S. FDA for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for the treatment of insomnia, a sleep-wake disorder. ...
Press Releases
BHS-Sonthofen: New approaches in removing catalysts from API slurries
As the pharmaceutical industry has changed and grown in the last two decades, there are increasing concerns about the safe handling of active pharmaceutical ingredients (APIs)– particularly in the process of removing catalysts from API slurries which has a...
Press Releases
Chinese API Market Growing Strongly, CPhI China Assisting Enterprises with the Transformation, Innovation, and Comprehensive Upgrading
As China continues to advance from a big country in pharmaceuticals to a power in pharmaceuticals, and the global economy maintains good trends, the main business income of API manufacturing in China has reached RMB499.1 billion, growing by 14.68%...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read